Erector Spinae Plane Block in Renal Transplantation Donors

Effects of Erector Spinae Plane Block on Opioid Consumption in Renal Transplantation Donors

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04863716

Enrollment

Registered

2021-04-28

Start date

2021-04-28

Completion date

2022-04-14

Last updated

2022-09-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Erector Spinae Plane Block, Laparoscopic Nephrectomy, Renal Transplantation

Keywords

Laparoscopic Nephrectomy, Erector Spinae Plane Block

Brief summary

Erector Spina Plan Block (ESPB) is a relatively new, easy-to-apply and safe regional anesthesia technique used to provide postoperative analgesia in various surgeries. Studies showing the clinical benefits of Erector Spina Plan block in renal transplantation surgery are limited to case reports. In this study, the effect of Erector Spina Plan Block on opioid consumption in postoperative period on donor patients who will undergo laparoscopic nephrectomy in renal transplantation surgery will be examined prospectively. The aim of the study is to provide analgesia to donor patients using less opioids by Erector Spina Plan Block and provide enhanced recovery.

Interventions

PROCEDUREErector Spinae Plane Block

Erector Spinae Plane Block will be administered before the surgery.

PROCEDUREIntravenous fentanyl patient control device

24-hour fentanyl consumption will be recorded.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Yes

Inclusion criteria

* Donor patients scheduled for elective nephrectomy in renal transplantation surgery * ASA I-II * Patients who are aged between 18-75

Exclusion criteria

* Skin infection at the Erector Spina Plan Block area * Coagulation disorder or using anticoagulant drugs * End-stage organ and system failure * Severe pulmonary and/or cardiovascular problems * Substance addiction or known psychiatric or mental problems * Chronic painkiller usage

Design outcomes

Primary

Measure	Time frame	Description
Fentanyl consumption	Postoperative 24 hours	The amount of fentanyl required by the patient and given by the device will be recorded for the first 24 hours.

Secondary

Measure	Time frame	Description
Visual Analog Scale	Postoperative 24 hours	Pain of patients will be evaluated and recorded according to the Visual Analog Scale.
Modified Aldrete Score	Postoperative 1 hour	Modified Aldrete Score will be used in patient recovery, and scores will be recorded at 5 minute intervals.

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026